Holen Sie sich die Stockscreener-App
85.66
1.01%
0.86
Handel nachbörslich:
85.66
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$84.80
Offen:
$85.18
24-Stunden-Volumen:
7.25M
Relative Volume:
1.64
Marktkapitalisierung:
$49.71B
Einnahmen:
$5.88B
Nettoeinkommen (Verlust:
$1.34B
KGV:
36.47
EPS:
2.3489
Netto-Cashflow:
$799.60M
1W Leistung:
+3.11%
1M Leistung:
-0.42%
6M Leistung:
+15.79%
1J Leistung:
+15.87%
1-Tages-Spanne:
$84.84
$85.82
1-Wochen-Bereich:
$81.85
$86.19
52-Wochen-Spanne:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
85.66 | 49.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
125.45 | 217.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
95.61 | 142.48B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.20 | 135.04B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.63 | 126.25B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
How JP Morgan’s Upgrade and 2026 Conference Spotlight Will Impact Edwards Lifesciences (EW) Investors - simplywall.st
Edwards Lifesciences Corporation $EW Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Profit Review: How Edwards Lifesciences Corporation stock compares to industry benchmarksPrice Action & Capital Efficiency Focused Ideas - ulpravda.ru
Edwards Lifesciences Corporation (EW) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
How Edwards Lifesciences Corporation stock performs in rate cut cyclesJuly 2025 Setups & Daily Profit Focused Stock Screening - ulpravda.ru
What makes Edwards Lifesciences Corporation stock attractive to growth fundsJuly 2025 Opening Moves & Community Verified Trade Alerts - ulpravda.ru
Edwards Lifesciences (NYSE:EW) Updates FY 2025 Earnings Guidance - MarketBeat
Amiral Gestion Has $21.99 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
How Edwards Lifesciences Corporation stock compares to industry benchmarks - ulpravda.ru
JP Morgan Upgrades Edwards Lifesciences (EW) Rating to Overweigh - GuruFocus
Edwards Lifesciences (NYSE:EW) Shares Little Changed in NYSE Session - Kalkine Media
Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Orser Capital Management LLC Acquires Shares of 27,953 Edwards Lifesciences Corporation $EW - MarketBeat
JPMorgan Upgrades Edwards Lifesciences to Overweight From Neutral, Adjusts PT to $100 From $90 - marketscreener.com
JPMorgan upgrades Edwards Lifesciences stock rating to Overweight - Investing.com
Canaccord Genuity Lowers Price Target for Edwards Lifesciences (EW) to $87 | EW Stock News - GuruFocus
Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider - GlobeNewswire Inc.
Edwards Lifesciences (EW): Reassessing Valuation After Strong Sales Growth and Upgraded Guidance - simplywall.st
Edwards seeks a TAVR two-fer in Medicare coverage petition - BioWorld MedTech
Transcatheter heart valves market to enjoy solid growth - MassDevice
Baird Trims Price Target on Edwards Lifesciences to $87 From $88, Maintains Neutral Rating - marketscreener.com
CMS accepts Edwards request for national TAVR coverage review - MassDevice
Shorepoint Capital Partners LLC Invests $5.19 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW): Analyst Rating Maintained, Price Targ - GuruFocus
BTIG reiterates Buy rating on Edwards Lifesciences stock amid TAVR review - Investing.com
Edwards Lifesciences Resolves $140 Million Harpoon Medical Case - Bloomberg Law News
Edwards Lifesciences Completes Key Study on SAPIEN XT THV - TipRanks
Squarepoint Ops LLC Acquires 50,924 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
Is There Now An Opportunity In Edwards Lifesciences Corporation (NYSE:EW)? - Yahoo Finance
Holocene Advisors LP Buys 1,223,460 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
934,449 Shares in Edwards Lifesciences Corporation $EW Bought by Hudson Bay Capital Management LP - MarketBeat
Hudson Bay Capital Management LP Invests $73.08 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Liontrust Investment Partners LLP Has $112.04 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
What Edwards Lifesciences (EW)'s Upgraded Guidance And Earnings Momentum Means For Shareholders - simplywall.st
Edwards Lifesciences (NYSE:EW) VP Donald Bobo Jr Sells 11,386 Shares - MarketBeat
Elevatus Welath Management Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Bellevue Group AG Sells 82,892 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Banque Transatlantique SA Purchases 24,575 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell: Heisz Stone Sells Shares of Edwards Lifesciences C - GuruFocus
VP Bobo Jr Sells 11,386 ($953.7K) Of Edwards Lifesciences Corp [EW] - TradingView — Track All Markets
Edwards Lifesciences (EW) executive reports stock sales and 7,100-share gift - Stock Titan
Edwards Lifesciences (EW) officer exercises options and sells 1,019 shares - Stock Titan
Edwards Lifesciences (EW) director reports sale of 2,615 shares at $83.41 - Stock Titan
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Shareholder Bobo Donald E Jr Fam Trust Files To Sell 5,900 Of Edwards Lifesciences Corp [EW] - TradingView — Track All Markets
EW (NYSE: EW) Rule 144 filing details planned sale of 5,900 shares - Stock Titan
Edwards Lifesciences (EW) insider plans Rule 144 sale of 2,615 common shares - Stock Titan
Edwards Lifesciences (NYSE: EW) insider files Form 144 to sell 5,487 shares - Stock Titan
Edwards Lifesciences Reports Strong Earnings and Growth - MSN
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):